BioMarin Pharmaceutical (BMRN)
(Delayed Data from NSDQ)
$61.93 USD
+1.62 (2.69%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $61.92 -0.01 (-0.02%) 5:28 PM ET
3-Hold of 5 3
B Value B Growth F Momentum B VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
BMRN 61.93 +1.62(2.69%)
Will BMRN be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for BMRN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BMRN
BioMarin Beats on Q2 Earnings & Sales, Stock Gains on Raised '25 View
BioMarin (BMRN) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
BMRN: What are Zacks experts saying now?
Zacks Private Portfolio Services
BioMarin Pharmaceutical (BMRN) Q2 Earnings and Revenues Surpass Estimates
ANI Pharmaceuticals (ANIP) Earnings Expected to Grow: What to Know Ahead of Q2 Release
BioMarin Pharmaceutical (BMRN) Reports Next Week: Wall Street Expects Earnings Growth
Other News for BMRN
BMRN Makes Bullish Cross Above Critical Moving Average
UBS Updates Its Analyst Rating and Target Price for BMRN | BMRN Stock News
UBS Adjusts Price Target for BioMarin (BMRN) to $114
BioMarin price target raised by $1 at UBS
BioMarin: Acquisition Of Inozyme Brings Forth Late-Stage ERT BMN 401